Liraglutide effectiveness in preoperative weight-loss for bariatric-metabolic surgery evaluated

Severe obesity significantly reduces wellbeing and life expectancy, often shortening life by 8 to 10 years. Preoperative management of patients with severe obesity, particularly achieving adequate weight-loss, is crucial for improving surgical outcomes and reducing morbidity associated with bariatric-metabolic surgery. Current strategies often fall short, necessitating novel approaches. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is a recognized pharmacological tool for weight management, making its potential role in this critical preoperative phase a relevant area of investigation.

The study investigated the effectiveness of the GLP-1 analogue Liraglutide in promoting preoperative weight-loss. The intervention targeted patients preparing for bariatric-metabolic surgery. The abstract does not specify the study design, patient n, Liraglutide dose, administration route, treatment duration, or the primary endpoint measured. No control arm or specific assay methods (ELISA, qPCR) were detailed in the provided information.

The abstract explicitly states that "The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study." However, the provided research record does not include any specific findings, numerical results, statistical data (e.g., p-values, percent weight loss, fold-changes), or details on observed effects on GLP-1R signaling or related metabolic pathways. No quantitative outcomes or comparisons were reported, thus no key results can be extracted for this section.